| Bioactivity | Trafermin is a recombinant human basic fibroblast growth factor (rhbFGF). Trafermin is a potent FGFR inhibitor. Trafermin improves degree of re-epithelialization. Trafermin can be used in research in skin healing[1]. |
| In Vivo | Trafermin (trafermin is applied by spray) promotes skin healing in with cutaneous ulcer model mice and wound healing rates are 47.40% at 7 days and 93.61% at 14 days. Trafermin increases the expression of TGF-β1 and α-SMA[1]. |
| Name | Trafermin |
| CAS | 131094-16-1 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ueno K, et, al. Treatment of refractory cutaneous ulcers with mixed sheets consisting of peripheral blood mononuclear cells and fibroblasts. Sci Rep. 2016 Jun 22;6:28538. [2]. Sumikawa S, et, al. Effect of basic fibroblast growth factor on radiation-induced oral mucositis in male Syrian hamsters. Int J Radiat Biol. 2017 Dec;93(12):1343-1349. |